Treatment of dyslipidemia in patients with type 2 diabetes Review article
Article Sidebar
Published:
Mar 31, 2023
Keywords:
type 2 diabetes, dyslipidemia, diabetic retinopathy, diabetic nephropathy, heart failure, cardiovascular disease risk
Main Article Content
Abstract
Treatment of dyslipidemia is one of the most important goals in management of type 2 diabetes. Achieving LDL cholesterol, non-HDL cholesterol and triglycerides target levels can reduce cardiovascular disease risk, which is increased in subjects with diabetes. Furthermore, it is important to prevent or delay comorbidities. There are data suggesting that fenofibrate treatment can delay the progression of chronic kidney disease and diabetic retinopathy. Moreover, it decreases the risk of hospitalization for heart failure and all cause mortality. Because of pleiotropic effects of fenofibrate, it seems that regular treatment in patients with diabetes provides additional benefits beyond improving lipid profile.
Article Details
How to Cite
Gajda, P., & Dzida , G. (2023). Treatment of dyslipidemia in patients with type 2 diabetes. Medycyna Faktow (J EBM), 16(1(58), 17-20. https://doi.org/10.24292/01.MF.0123.03
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Gajewski P, Szczeklik A. Interna Szczeklika 2021. Medycyna Praktyczna, Kraków 2021.
2. Czupryniak L. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2022. Stanowisko Polskiego Towarzystwa Diabetologicznego. Curr Top Diabetes. 2022; 2(1): 1-134.
3. Gunwal D, Dutt BB, Choudhary M et al. A comprehensive review on the drug: fenofibrate. IJRPS. 2021; 12(3): 2164-72. http://doi.org/10.26452/ijrps.v12i3.4829.
4. Szymański FM, Mickiewicz A, Dzida G et al. Management of dyslipidemia in Poland: Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. The Fourth Declaration of Sopot. Cardiol J. 2022; 29(1): 1-26. http://doi.org/10.5603/CJ.a2021.0147.
5. Zhu L, Hayen A, Bell KJL. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. Cardiovasc Diabetol. 2020; 19(1): 28. http://doi.org/10.1186/s12933-020-01002-x.
7. Viñas Esmel E, Naval Álvarez J, Sacanella Meseguer E. The legacy effect in the prevention of cardiovascular disease. Nutrients. 2020; 12(11). http://doi.org/10.3390/nu12113227.
8. Preiss D, Spata E, Holman RR et al. Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials. Diabetes Care. 2022; 45(1): e1-e2. http://doi.org/10.2337/dc21-1439.
9. Scott R, O’Brien R, Fulcher G et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009; 32(3): 493-8. http://doi.org/10.2337/dc08-1543.
10. Chew EY, Davis MD, Danis RP et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology. 2014; 121(12): 2443-51. http://doi.org/10.1016/j.ophtha.2014.07.019.
11. Diabetes Canada Clinical Practice Guidelines Expert Committee; Altomare F, Kherani A, Lovshin J. Retinopathy. Can J Diabetes. 2018; 42(suppl 1): S210-S216. http://doi.org/10.1016/j.jcjd.2017.10.027.
12. The Royal Australian College of General Practitioners, (2020) Management of type 2 diabetes: a handbook for general practice. RACGP, East Melbourne, VIC, Australia.
13. Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010; 375: 1875-84.
14. The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye. (FAME 1 EYE). ClinicalTrials.gov Identifier: NCT01320345.
15. Lowering Events in Non-proliferative Retinopathy in Scotland (LENS). ClinicalTrials.gov Identifier: NCT03439345.
16. Morieri ML. Heart Failure Burden in Diabetes: Can Fenofibrate Provide Additional hope? Diabetes Care. 2022; 45(7): 1500-02. http://doi.org/10.2337/dci22-0012.
2. Czupryniak L. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2022. Stanowisko Polskiego Towarzystwa Diabetologicznego. Curr Top Diabetes. 2022; 2(1): 1-134.
3. Gunwal D, Dutt BB, Choudhary M et al. A comprehensive review on the drug: fenofibrate. IJRPS. 2021; 12(3): 2164-72. http://doi.org/10.26452/ijrps.v12i3.4829.
4. Szymański FM, Mickiewicz A, Dzida G et al. Management of dyslipidemia in Poland: Interdisciplinary Expert Position Statement endorsed by the Polish Cardiac Society Working Group on Cardiovascular Pharmacotherapy. The Fourth Declaration of Sopot. Cardiol J. 2022; 29(1): 1-26. http://doi.org/10.5603/CJ.a2021.0147.
5. Zhu L, Hayen A, Bell KJL. Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. Cardiovasc Diabetol. 2020; 19(1): 28. http://doi.org/10.1186/s12933-020-01002-x.
7. Viñas Esmel E, Naval Álvarez J, Sacanella Meseguer E. The legacy effect in the prevention of cardiovascular disease. Nutrients. 2020; 12(11). http://doi.org/10.3390/nu12113227.
8. Preiss D, Spata E, Holman RR et al. Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials. Diabetes Care. 2022; 45(1): e1-e2. http://doi.org/10.2337/dc21-1439.
9. Scott R, O’Brien R, Fulcher G et al. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care. 2009; 32(3): 493-8. http://doi.org/10.2337/dc08-1543.
10. Chew EY, Davis MD, Danis RP et al. The effects of medical management on the progression of diabetic retinopathy in persons with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Eye Study. Ophthalmology. 2014; 121(12): 2443-51. http://doi.org/10.1016/j.ophtha.2014.07.019.
11. Diabetes Canada Clinical Practice Guidelines Expert Committee; Altomare F, Kherani A, Lovshin J. Retinopathy. Can J Diabetes. 2018; 42(suppl 1): S210-S216. http://doi.org/10.1016/j.jcjd.2017.10.027.
12. The Royal Australian College of General Practitioners, (2020) Management of type 2 diabetes: a handbook for general practice. RACGP, East Melbourne, VIC, Australia.
13. Jun M, Foote C, Lv J et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010; 375: 1875-84.
14. The Fenofibrate And Microvascular Events in Type 1 Diabetes Eye. (FAME 1 EYE). ClinicalTrials.gov Identifier: NCT01320345.
15. Lowering Events in Non-proliferative Retinopathy in Scotland (LENS). ClinicalTrials.gov Identifier: NCT03439345.
16. Morieri ML. Heart Failure Burden in Diabetes: Can Fenofibrate Provide Additional hope? Diabetes Care. 2022; 45(7): 1500-02. http://doi.org/10.2337/dci22-0012.